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Abstract
Background
Chronic lymphocytic leukemia and small lymphocytic lymphoma are 2 different presenta-
tions of the most common B-cell neoplasm in western countries (CLL/SLL). In this disease,
kidney involvement is usually silent, and is rarely reported in the literature. This study pro-
vides a clinicopathological analysis of all-cause kidney disease in CLL/SLL patients.
Methods
Fifteen CLL/SLL patients with kidney biopsy were identified retrospectively. Demographic,
clinical, pathological and laboratory data were assessed at biopsy, and during follow-up.
Results
At biopsy 11 patients presented impaired renal function, 7 patients nephrotic syndrome, 6
patients dysproteinemia, and 3 patients cryoglobulinemia. Kidney pathology revealed CLL/
SLL-specific monoclonal infiltrate in 10 biopsies, glomerulopathy in 9 biopsies (5 membrano-
proliferative glomerulonephritis, 2 minimal change disease, 1 glomerulonephritis with orga-
nized microtubular monoclonal immunoglobulin deposits, 1 AHL amyloidosis). Five patients
presented interstitial granulomas attributed to CLL/SLL. After treatment of the hematological
disease, improvement of renal function was observed in 7/11 patients, and remission of ne-
phrotic syndrome in 5/7 patients. During follow-up, aggravation of the kidney disease sys-
tematically occurred in the absence of favorable response to hematological treatment.
Conclusions
A broad spectrum of kidney diseases is associated with CLL/SLL. In this setting, kidney bi-
opsy can provide important information for diagnosis and therapeutic guidance.
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Introduction
Kidney diseases are frequently associated with hematologic malignancies. Depending on the
type and stage of the malignancy, the spectrum of kidney pathology can be particularly wide,
including immune-mediated glomerulonephritis, interstitial monoclonal infiltration and
tubular obstruction.
Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are two
different presentations of the most frequent B-cell neoplasm in adults in Western countries,
with an annual incidence of 4–30 cases per 100,000 persons per year [1,2]. Although most pa-
tients remain asymptomatic, the clinical features of CLL/SLL are highly variable, including pre-
sentation, course and outcome. Unlike renal involvement in monoclonal gammapathies, the
description of kidney diseases associated with CLL/SLL is currently limited to case reports and
small series of immune-mediated glomerulopathies and interstitial infiltration by monoclonal
lymphocytes [3–9].
In this context, the objective of the present study was to provide a systematic description of
kidney pathology and clinical characteristics in a well characterized population of CLL/SLL pa-
tients referred for kidney biopsy, in order to better delineate the spectrum and the relative fre-
quency of kidney diseases associated with CLL/SLL.
Subjects and Methods
Patients
This study included all the CLL/SLL patients who underwent a kidney biopsy in Haute-
Normandie (1 800 000 inhabitants) between 1989 and 2014. During the study period, 3950 kid-
ney biopsies were performed in the 8 hospitals and clinics of the region. All the biopsies were
processed and analyzed in a single central reference pathology department, where the samples
were systematically included in a tissue bank (Pathology Department, Rouen University Hospi-
tal, Rouen, France). Finally, after screening of the central patient database, 15 patients (20 biop-
sies) were included on the basis of a CLL/SLL diagnosis ascertained before or at the time of the
kidney biopsy. Two of the 15 patients were reported in a previous study specifically focusing
on glomerulonephritis in CLL/SLL [8]. Demographic, clinical and laboratory data, including
results of the nephrological investigations prompting kidney biopsy, were recorded at time of
the biopsy, and from the initial to the latest follow-up.
CLL/SLL was diagnosed according to the WHO classification (ICD-0 9823/3) [1,2]. An in-
dicative extrapolation based on data from the Basse-Normandie CLL/SLL registry estimates
that approximately 525 new cases of SLL and 2875 of CLL were diagnosed in Haute-Norman-
die over the 25-year study period. The diagnosis of CLL requires the presence of at least 5.109 B
lymphocytes /l in the peripheral blood, over> 3 months, with evidence of monoclonality
(CD5, CD19, CD20, CD23) [1,2]. CLL is distinguishable from SLL by its leukemic appearance.
The definition of SLL requires a histological analysis of lymph node biopsy, and the clinical
presentation includes lymphadenopathy and/or splenomegaly. In this case, lymph node histol-
ogy shows small lymphocytes with condensed chromatin and, occasionally, small nucleolus.
Large lymphoid cells with more prominent nucleoli and dispersed chromatin are typically
present, and are usually clustered in pseudofollicles. The Binet staging system classifies CLL in
stages A, B, or C according to the number of lymphoid tissues involved (enlarged lymph nodes
in the neck, groin, underarms, hepatomegaly or splenomegaly), and to the presence of anemia
and thrombocytopenia. Matutes score is based on the most common marker profile in CLL
(CD5+, CD23+, FMC7- and weak surface immunoglobulin (SIg) and CD22), and is used to
distinguish between typical (Matutes 4 and 5) and atypical CLL, by assigning scores that range
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from 5 to 0 [10]. General signs were defined as A: no general sign; or B: weight loss> 10% in 6
months, and/or fever> 38°C without alternative diagnosis and/or nocturnal sweating. Tumor-
al syndrome was defined as the presence of lymphadenopathy and/or extrarenal organ infiltra-
tion (hepatomegaly, splenomegaly). Hematological response to treatment was defined
according to the reference guidelines [1]. Dysproteinemias were identified by serum protein
immunoelectrophoresis and immunofixation.
Nephrotic syndrome (NS) was defined as proteinuria> 3 g/d with albuminemia< 30 g/l.
Complete remission was defined as proteinuria< 0.3 g/d, partial remission as proteinuria
< 3 g/d, and relapse as proteinuria> 3g/d after initial remission [11]. Acute renal failure was
defined by an increase in plasma creatinine> 26.5 micromol/l and/or>150% baseline value, ac-
cording to the Acute Kidney Injury Network (AKIN) criteria [12]. Kidney function improvement
was defined as a decrease in plasma creatinine> 10%, with persistence> 3 months. Chronic kid-
ney disease was defined as a decrease in MRDR eGFR< 90 ml/min/1.73 m² with persistence> 3
months [13].
Kidney pathology
The 20 biopsies were processed in a standardized manner in Rouen pathology department.
Light microscopy analysis was performed after fixation in Dubosq Brazil solution, 2-μm paraf-
fin section, and coloration by Masson trichrome, hematoxylin & eosin, Marinozzi silver, and
Congo red stainings. Standardized immunofluorescence was performed retrospectively in
2014. 3-μm cryostat sections were incubated with FITC-conjugated antibodies to human Ig
gamma, alpha, mu, kappa, and lambda light chains, C3, C4, C1q, fibrinogen, albumin, CD5,
CD20, CD23, CD3, Cyclin D1 and CD10. The biopsies were reanalyzed in a blinded fashion by
2 experienced kidney and hematology pathologists. Ultrastructural electron microscopy was
performed in 7 patients.
Ethical requirements
This study was in accordance with the Helsinki declaration, and was approved by the local eth-
ics board for non-invasive health research (Comité d'Ethique pour la Recherche Non Interven-
tionnelle CERNI N°E-2014-11, for the Centre de Protection des Personnes Nord-Ouest-I,
Rouen University Hospital, Rouen, France), which waived the need for informed consent in
this retrospective analysis.
Results
Clinical presentation at kidney biopsy
The clinical features at biopsy are presented in Table 1. The CLL/SLL had been diagnosed be-
fore the nephropathy in 7/15 cases, with a mean interval of 61 months from the hematological
to the nephrological diagnosis in this setting (range 19–156 months). General symptoms were
present in 7/15 patients, and 11/15 patients presented lymphadenopathy, hepatomegaly, and/
or splenomegaly. Extrarenal symptoms were present in 4/15 patients (peripheral neuropathy,
arthralgia, skin vasculitis, cholestasis).
Laboratory and radiological data
In all patients, the kidney biopsy was performed because of renal failure and/or significant pro-
teinuria. The laboratory and radiological results are presented in Tables 2 and 3. MDRD
eGFR< 60 ml/min/1.73m² was found in 11/15 patients, (mean 23 ml/min/1.73m², range
7–38). NS was present in 7/15 patients, while normal proteinuria and urine sediment were
Kidney Pathology in CLL/SLL
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found in 2 cases. The hematological work-up revealed dysproteinemia in 6/15 patients (cases 4,
5, 10, 11, 12, 14), with cryoglobulinemia in 3 cases (cases 10, 11, 12). Complement activation
was found in 5/15 patients (cases 9, 10, 11, 12, 13). Enlarged kidneys were noticed in one pa-
tient (case 6).
Pathology
Tables 4 and 5 summarize the conclusions of the kidney biopsy analyses. Monoclonal infiltra-
tion was evidenced in 10/15 biopsies. All of these 10 patients presented specific and abundant
tumoral infiltration, which was generally associated with non specific reactive lymphocytes.
Table 1. Clinical characteristics at biopsy.
Case Sex Age at
biopsy
Interval CLL/
SLL
Nephropathy
(m)
CLL/
SLL
Hematological
treatment
before biopsy
Comorbidity HTN Extracellular
ﬂuid
expansion
Extrarenal
symptoms
General
symptoms
A/B
Tumoral
syndrome
Interstitial nephropathy: isolated speciﬁc tumoral interstitial inﬁltrate +/- CLL/SLL-related granulomatosis
1 M 65 36 p CLL N HTN, smoking,
dyslipidemia,
spondylarthropathy
Y N N A Y
2 M 69 19 CLL Cs HTN, smoking,
T2D, stroke,
alcoholism
Y Y N B Y
3 F 51 36 CLL R-FC HTA Y Y N A Y
4 M 57 96 CLL N Smoking,
peripheral artery
disease
Y N N A Y
5 M 77 62 CLL R-FC HTN, smoking,
sleep apnoea
syndrome
Y N N B Y
5bis 78 R-FC
+ Chlorambucil
Y N N A Y
6 M 67 0 CLL N Smoking Y N N B N
Glomerular lesions associated or not with interstitial nephropathy
7 M 73 156 CLL N HTN, smoking Y Y N A N
8 F 57 42 CLL N Preeclampsia N Y N A N
8bis 60 Cs Y Y N A N
9 M 62 0 SLL N HTN Y Y N B Y
10 F 67 19 p CLL N N Y Y Y A N
10bis 69 N Y Y Y B N
11 F 65 0 SLL N Dyslipidemia Y Y Y A Y
12 F 63 19 CLL Chlorambucil T2D, peripheral
artery disease
Y Y Y A Y
12bis 71 Chlorambucil Y Y N B N
13 M 76 0 SLL N N Y Y N B Y
14 M 62 0 CLL N Dilated
cardiomyopathy
N Y Y B Y
15 F 67 0 CLL N N Y Y N B Y
15bis 78 Chlorambucil
+ Fludarabine
Y Y N A Y
p, CLL/SLL diagnosis post-nephropathy; Cs, corticosteroids; R-FC, rituximab+ﬂudarabine+cyclophosphamide; HTN, hypertension; T2D, type 2 diabetes;
Y, yes; N, no.
doi:10.1371/journal.pone.0119156.t001
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The common morphological feature in these cases was a diffuse nodular infiltration, composed
of small mature lymphocytes, with small hyperchromatic nuclei, expanding the interstitium at
the expense of the tubular structures, the peritubular capillaries, and less frequently the glomer-
uli (Fig. 1). Immunohistochemistry revealed monotypic lymphocytes (CD20+, CD5+, Cyclin
D1-, CD10-). Six patients presented interstitial infiltration without glomerular lesions. Four
had a severe infiltration, associated with GFR< 30 ml/min/1.73m², which represented the in-
dication for kidney biopsy. There was no clear association between the intensity of interstitial
infiltration, the CLL stage, and the acute vs chronic presentation of kidney failure. A tumoral
syndrome was found in 9/10 of the patients with interstitial infiltration, compared to 2/5 pa-
tients without interstitial infiltration. Acute kidney injury was attributed to tubular necrosis in
2 patients (cases 6 and 9), and to interstitial infiltration in cases 2, 5, and 12. In the patients
with AKI occurring in a context of MPGN, no extracapillary proliferation was found.
Table 2. Laboratory and radiological features.
Case AKI/
CKD
P. creatinine
(micromol/l)
MDRD eGFR (ml/
min)
Proteinuria (g/
d) P. albumin
(g/l)
Hematuria Leukocyturia Dysproteinemia Fanconi
Syndrome
Complement Kidney
length (R/
L, mm)
Interstitial nephropathy: isolated speciﬁc tumoral interstitial inﬁltrate +/- CLL/SLL-related granulomatosis
1 CKD 185 / 34 0.3 / 56 N N N N Normal 101 / 110
2 AKI 743 / 7 1 / 39 Y Y N N Normal 120 / 120
3 CKD 178 / 28 0.9 / 43 N Y N N Normal 120 / 120
4 CKD 194 / 36 0.3 / 49 N N IgG kappa 4.6 g/l /
kappa BJ
Y Normal 120 / 107
5 CKD 247 / 24 0.8 / 44 N N Lambda BJ N Normal 113 / 113
5bis AKI/
CKD
638 / 8 1.4 / 41 N N N Y Normal Normal
6 AKI 616 / 8 1.2 / 36 Y Y N N Normal >120 /
>120
Glomerular lesions associated or not with interstitial nephropathy
7 CKD 193 / 38 3.8 / 44 Y N N N Normal 118 / 108
8 N 74 / 72 6.1 / 20 N N N N Normal Normal
8bis N 71 / 76 4.6 / 32 Y N IgG lambda N Normal Normal
9 AKI 178 / 36 6.3 / 21 Y N N N Low C3 Normal
10 N 71 / 75 1.2 / 43 Y Y Type II cryoglobulin N Low C3 and
C4
117 / 112
10bis CKD 96 / 53 13 / 19 Y Y Type II cryoglobulin N Low C3 and
C4
ND
11 CKD 168 / 28 14 / 25 Y Y Type I cryoglobulin,
IgG kappa
N Low C3 and
C4
103 / 108
12 AKI/
CKD
536 / 7 >3 / 30 Y Y Type I cryoglobulin,
IgG kappa
N Low C4 118 / 123
12bis AKI/
CKD
769 / 5 4.5 / 25 Y Y IgG kappa N Normal 95 / 95
13 N 100 / 67 >6 / 24 Y Y N N Low C3 and
C4
Normal
14 CKD 470 / 12 7 / 24 N N IgG lambda N ND 116 / 100
15 N 79 / 67 6.1 / 30 Y Y N N Normal Normal
15bis CKD 530 / 7 >13 / 28 Y Y N N Normal Normal
AKI, acute kidney injury; CKD, chronic kidney disease; P, plasma; BJ, Bence Jones proteinuria; ND, no data available.
doi:10.1371/journal.pone.0119156.t002
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Interstitial granulomas were found in 5/15 patients. Light microscopy revealed florid inter-
stitial gigantocellular granulomas, surrounded by lymphocytes (Fig. 2). No tubular basement
membrane rupture, cellular necrosis or microcristalline precipitation was observed, and Peri-
odic Acid Schiff, Ziehl and Grocott stainings revealed no microorganism. Immunofluorescence
showed no specific interstitial deposit. Granulomas were a prominent feature in cases 4, 6 and
on the 2nd biopsy of case 8. The granulomas were associated with monotypic interstitial infil-
tration (cases 4, 5, 6), or with glomerular deposits (cases 14, 15). No extrarenal granuloma was
found in these patients.
Nine patients presented glomerular lesions, of which 4/9 were associated with monoclonal
interstitial infiltration. Membranoproliferative glomerulonephritis (MPGN) was present in 5
patients (cases 9–13). Light microscopy revealed typical mesangial and/or endocapillary prolif-
eration, double contours of the basement membrane, and endomembranous deposits (Fig. 3).
The deposits were related to a circulating cryoglobulin in cases 10–12. In these 3 patients an
important polymorphic infiltration with polymorphonuclear cells, lymphocytes and macro-
phages associated with endomembranous deposits was responsible for the formation of pseu-
dothrombi in capillary loops, and fibrinoid deposits in one patient (case 10). The
ultrastructural study revealed proliferative mesangial cells, podocyte foot process fusion, and
endomembranous homogeneous granular deposits. The immunofluorescence confirmed the
Table 3. Laboratory and radiological features.
Case Lymphocyte count
(/mm3)
Cytopenia
(0;1;2)
Blood ﬂow cytometry Matutes Bone marrow lymphocyte
inﬁltration
Binet
stage
Interstitial nephropathy: isolated speciﬁc tumoral interstitial inﬁltrate +/- CLL/SLL-related granulomatosis
1 16000 0 Lambda, CD5+ CD19+ CD23+ CD38- SmIg
strong
2 76% A
2 70680 2 (Hb,platelets) Lambda, CD5+ CD19+ ND 62% C
3 1380 0 Kappa, CD5+ CD19+ CD23+ CD38- 5 ND B
4 102000 1 (platelets) CD5+ CD19+ CD23+ FMC7- SmIg weak 5 35% B
5 102300 1 (platelets) Lambda, CD5+ CD19+ CD23+ FMC7-
CD38-
5 ND C
5bis 7605 2 (Hb, platelets) 5 ND C
6 80170 1 (Hb) CD5+ CD19+ CD23+ FMC7- CD38- CD79b
weak SmIg weak
5 ND A
Glomerular lesions associated or not with interstitial nephropathy
7 27200 0 Kappa, CD5+ CD19+ CD23+ 5 ND A
8 36800 0 Lambda, CD5+ CD19+ SmIg weak ND 75% A
8bis 8100 0 ND ND A
9 3652 1 (Hb) CD5+ CD19+ CD23+ CD38+ SmIg strong / ND /
10 3250 0 Kappa, CD5+ CD19+ ND 74% A
10bis 6960 1 (Hb) Kappa, CD5+ CD19+ ND ND ND
11 7691 1 (Hb) Kappa, CD5+ CD19+ CD23- FMC7+ CD79b
+ weak SmIg weak
/ 82% /
12 7100 0 Kappa, CD5+ CD19+ CD23 weak FMC7+ ND 75% B
12bis 11590 2 (Hb, platelets) ND 85% C
13 10350 1 (Hb: AIHA) ND / 78% /
14 7636 0 Lambda, CD5- CD19- SmIg strong ND 37% A
15 9870 1 (Hb) Lambda, CD5+ CD19+ CD23+ SmIg weak 5 49% C
15bis 1110 1 (platelets) 5 55% C
AIHA, autoimmune hemolytic anemia; SmIg, surface membrane immunoglobulin; Hb, hemoglobin; ND, no data available.
doi:10.1371/journal.pone.0119156.t003
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Table 4. Kidney biopsy pathology.
Case Light microscopy Glomerular
immunoﬂuorescence
Inﬁltrate
immunohistochemistry
Electron microscopy Deﬁnite diagnosis
Interstitial nephropathy: isolated speciﬁc tumoral interstitial inﬁltrate +/- CLL/SLL-related granulomatosis
1 Mild monomorphic
diffuse inﬁltrate
Ig alpha Ig mu traces CD20+ CD5+ CD23- Cyclin
D1- CD10-
CLL inﬁltrate
2 Moderate monomorphic
diffuse inﬁltrate
Normal CD20+ CD5+ CD23- CD10-
Cyclin D1-
CLL inﬁltrate
3 Moderate monomorphic
focal inﬁltrate
Ig gamma Ig mu C3 C1q
traces
CD20+ CD5+ CD23- CD10-
Cyclin D1-
CLL inﬁltrate
4 Two monomorphic
nodules
Normal CD20+ CD5+ CD23- CD79a
weak CD10- (nodules)
CLL inﬁltrate
Granulomatous
reaction
Abundant interstitial
granulomas
Mild polymorphic diffuse
inﬁltrate
5 One interstitial
granuloma
ND CD20+ CD5+ CD23- CD10-
Cyclin D1-
CLL inﬁltrate
Granulomatous
reaction
Severe monomorphic
diffuse inﬁltrate
5bis Abundant interstitial
granulomas
Normal CD20+ CD5+ CD23- CD10- CLL inﬁltrate
Granulomatous
reaction
Severe monomorphic
diffuse inﬁltrate
6 Abundant epithelioid
non-necrotic peritubular
granulomas
Normal CD20+ CD5+ CD79a+ CD23-
CD10- Cyclin D1- CD1-
CLL inﬁltrate
Granulomatous
reaction
Severe monomorphic
diffuse inﬁltrate
Glomerular lesions associated or not to interstitial nephropathy
7 MCD Ig mu C3 C4 C1q traces CD20- CD3+ CD5+ CD19-
CD23- Cyclin D1-
MCD
Mild polymorphic diffuse
inﬁltrate
8 MCD ND / Foot process fusion MCD
8bis MCD Normal / MCD
9 MPGN with capillary
thrombi
Ig gamma Ig mu kappa
lambda C4 C1q, C3 traces
CD20+ CD5- CD23- Cyclin
D1- (nodule)
Abundant subendothelial
non-organized non-ﬁbrillar
deposits
MPGN
One monomorphic
nodule, mild
polymorphic inﬁltrate
10 MPGN with
endocapillary
proliferation
ND / Rare non-oriented cylindric
280-nm long 35-nm
diameter deposits
Cryoglobulin-related
MPGN
10bis MPGN with
endocapillary
proliferation and ﬁbrinoid
deposits
Ig gamma Ig alpha Ig mu
C1q C3 C4
/ Cryoglobulin-related
MPGN
Pseudo-thrombi
11 MPGN with endo- and
extra-capillary
proliferation
Ig gamma1 kappa C3, C1q
traces
CD20+ CD5+ CD23+ CD10- Subendothelial granular and
ﬁbrillar deposits
Cryoglobulin-related
MPGN CLL inﬁltrate
(Continued)
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presence of the circulating cryoglobulin within glomerular deposits. Hepatitis B, C, and HIV
serologies were negative in all patients. In patients 9 and 13 neither cryoglobulin nor dysprotei-
nemia were detected. Case 13 presented monotypic gamma and kappa deposits together with
positive C3 on immunofluorescence analysis, and decreased C3 and C4 in the peripheral blood
tests. Large endomembranous deposits characterized by 8-nm diameter microfibrillar struc-
tures, organized in 0.96-μm long and 0.45-μm large bundles composed of approximately 12 el-
ements were evidenced, leading to the diagnosis of fibrillary glomerulonephritis.
Patient 15 presented an immunotactoid glomerulonephritis with organized microtubular
monoclonal immunoglobulin deposits. Light microscopy revealed mesangial sclerosis with
focal mesangial proliferation (Fig. 4). Large globular deposits were observed in the capillary
Table 4. (Continued)
Case Light microscopy Glomerular
immunoﬂuorescence
Inﬁltrate
immunohistochemistry
Electron microscopy Deﬁnite diagnosis
Pseudo-thrombi No ﬁbrillary organization in
lymphocytes
Severe monomorphic
diffuse inﬁltrate
12 MPGN Pseudo-thrombi Ig gamma kappa C3 CD20+ CD5+ CD23- CD10-
Cyclin D1-
Cryoglobulin-related
MPGN CLL inﬁltrate
Moderate monomorphic
diffuse inﬁltrate
12bis MPGN Pseudo-thrombi Ig gamma kappa C3 CD20+ CD5+ CD23- CD10-
Cyclin D1-
Cryoglobulin-related
MPGN CLL inﬁltrate
Severe monomorphic
diffuse inﬁltrate
13 MPGN appearance Ig gamma kappa C3 ND Endomembranous non-
amyloid microﬁbrillar 8-nm
diameter deposits
Fibrillary
glomerulonephritis CLL
inﬁltrate
Moderate monomorphic
focal inﬁltrate
14 Amyloidosis Ig gamma lambda CD20+ CD5- CD23- CD10-
Cyclin D1-
Non-oriented multifocal
10-nm-large ﬁbers
AHL Amyloidosis
Granulomatous
reaction
Mild polymorphic
inﬁltrate
One interstitial
granuloma
15 Mesangial sclerosis Ig gamma lambda C3 CD20+ CD5+ CD23- Cyclin
D1-
Subendothelial organized
microtubular deposits
ITGN
One interstitial
granuloma
30-nm long external
diameter
CLL inﬁltrate
Mild monomorphic focal
inﬁltrate
Granulomatous
reaction
15bis Mesangial sclerosis and
proliferation, capillary
deposits, podocytosis
ND CD20+ CD5+ CD23- CD10-
Cyclin D1-
ITGN
Moderate polymorphic
multifocal inﬁltrate
CLL inﬁltrate
MPGN, membranoproliferative glomerulonephritis; AHL, heavy- and light-chain amyloidosis; ITGN, immunotactoid/microtubular glomerulonephritis; ND, no
data available
MCD, minimal change disease; MPGN, membranoproliferative glomerulonephritis; ND, no data available.
doi:10.1371/journal.pone.0119156.t004
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loops. Monotypic IgG lambda was found within the deposits, with endocapillary C3. The ultra-
structural analysis revealed subendothelial organized microtubular deposits, characterized by a
30-nm long external diameter.
Two patients presented minimal change lesions, with normal light microscopy, normal
immunofluorescence, and foot process effacement on the ultrastructural analysis (cases 7, 8).
Patient 14 had glomerular heavy- and light-chain amyloidosis (AHL) related to a circulating
IgG lambda monoclonal protein. Light microscopy found very large Congo red positive dichroic
deposits in the mesangium, the subendothelial space of glomerular capillaries, Bowman’s cap-
sule, the interstitium, the tubular basement membrane and the arterioles (Fig. 5). Immunofluo-
rescence revealed an equally intense staining for gamma and lambda chains, and ultrastructural
analysis showed that the deposits were composed by non-oriented 10-nm large fibers.
Evolution
The mean post-biopsy follow-up was 86 months (range 3–199 months) (Tables 6 and 7). All
but 1 patient (case 7) received corticosteroids and/or cytotoxic treatment. Two patients with se-
vere interstitial infiltration received methylprednisolone pulses followed by cytotoxic chemo-
therapy, with favorable renal outcomes (cases 2, 6).
Among the 7 patients presenting with NS and treated with cytotoxic agents, transient or
persistent complete remission was observed in 5 patients. Partial remission was observed in pa-
tient 9 (MPGN), while patient 14 (AHL amyloidosis) had a persistent NS. In 4 patients with
NS relapse observed during the follow-up, progression of the hematological malignancy was
Table 5. Kidney biopsy pathology.
Case Light microscopy Glomerular
immunoﬂuorescence
Inﬁltrate
immunohistochemistry
Electron microscopy Deﬁnite diagnosis
11 MPGN with endo- and extra-
capillary proliferation; Pseudo-
thrombi; Severe monomorphic
diffuse inﬁltrate
Ig gamma1 kappa C3,
C1q traces
CD20+ CD5+ CD23
+ CD10-
Subendothelial granular and
ﬁbrillar deposits; No ﬁbrillary
organization in lymphocytes
Cryoglobulin-related
MPGN CLL inﬁltrate
12 MPGN; Pseudo-thrombi;
Moderate monomorphic
diffuse inﬁltrate
Ig gamma kappa C3 CD20+ CD5+ CD23-
CD10- Cyclin D1-
Cryoglobulin-related
MPGN CLL inﬁltrate
12bis MPGN; Pseudo-thrombi;
Severe monomorphic diffuse
inﬁltrate
Ig gamma kappa C3 CD20+ CD5+ CD23-
CD10- Cyclin D1-
Cryoglobulin-related
MPGN CLL inﬁltrate
13 MPGN appearance; Moderate
monomorphic focal inﬁltrate
Ig gamma kappa C3 ND Endomembranous non-
amyloid microﬁbrillar 8-nm
diameter deposits
Fibrillary
glomerulonephritis CLL
inﬁltrate
14 Amyloidosis; Mild polymorphic
inﬁltrate; One interstitial
granuloma
Ig gamma lambda CD20+ CD5- CD23-
CD10- Cyclin D1-
Non-oriented multifocal
10-nm-large ﬁbers
AHL Amyloidosis
Granulomatous
reaction
15 Mesangial sclerosis; One
interstitial granuloma; Mild
monomorphic focal inﬁltrate
Ig gamma lambda C3 CD20+ CD5+ CD23-
Cyclin D1-
Subendothelial organized
microtubular deposits; 30-nm
long external diameter
ITGN; CLL inﬁltrate
Granulomatous
reaction
15bis Mesangial sclerosis and
proliferation; Capillary
deposits; Podocytosis;
Moderate polymorphic
multifocal inﬁltrate
ND CD20+ CD5+ CD23-
CD10- Cyclin D1-
ITGN; CLL inﬁltrate
MPGN, membranoproliferative glomerulonephritis; AHL, heavy- and light-chain amyloidosis; ITGN, immunotactoid/microtubular glomerulonephritis; ND, no
data available.
doi:10.1371/journal.pone.0119156.t005
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also present. In 7/11 patients presenting with decreased eGFR at biopsy the eGFR increased
after treatment. Four patients had a negative decline of eGFR after treatment, which occurred
in the absence of hematological response (cases 5, 12bis, 14, 15bis). Five patients had a second
kidney biopsy for relapse of NS or rapid decrease in eGFR. In all cases, the second kidney biop-
sy revealed progression of the renal lesions initially identified, with superimposed or increased
interstitial infiltration in cases 5, 12, and 15.
At the last follow-up, progression of the kidney disease had required extrarenal suppleance
therapy in 5 patients. Patient 6 needed transient hemodialysis, which was withdrawn after post-
treatment recovery of kidney function. The mean plasma creatinine at the end of the follow-up,
excluding the 5 patients requiring dialysis, was 122 micromol/l.
Discussion
This study attempted to better describe the spectrum of kidney pathology associated with CLL/
SLL. The first occurrence of kidney disease in CLL was described in 1957 by Scott et al, in a
Fig 1. CLL/SLL infiltrate (case 12). (a) Masson trichrome staining. (b) Specific immunostaining to human CD3. (c) Specific immunostaining to human CD5.
(d) Specific immunostaining to human CD20. Light microscopy, original magnification, X 40.
doi:10.1371/journal.pone.0119156.g001
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patient presenting with NS [14]. Subsequently, case reports and small series have underlined
the diversity of lesions which may be found in CLL/SLL, including interstitial infiltration, im-
mune-mediated glomerulonephritis, and drug toxicity. With the inclusion of 15 patients, the
present study provides the largest series of all-cause kidney disease in CLL/SLL currently re-
ported (Table 8). CLL is usually diagnosed in patients> 55 y (90%), with a sex ratio of 1.5 [15].
In this study the patients had a mean age 65.2 at the first kidney biopsy, younger than in the
CLL/SLL general population (mean age 72), suggesting that complications due to kidney in-
volvement can be diagnostic in CLL/SLL. Alternatively, patients with kidney disease could also
present with more aggressive forms of CLL/SLL.
Renal interstitial infiltration is a frequent finding in autopsy series of CLL patients, estimat-
ed between 44 and 90% of patients. The B-cell infiltrate can either be nodular or diffuse, and its
localization classically begins in the subcapsular cortex, at the corticomedullar junction, and
along the vasa recta [16,17]. In our patients presenting with isolated infiltrates the lymphocytes
were monotypic and presented a monomorphic, regular, and mature aspect, separating and di-
rectly infiltrating the tubular epithelium, surrounded by local accumulation of extracellular
matrix. Usually, the infiltration of the kidneys by monoclonal B cells is bilateral, asymptomatic,
and is diagnosed or suspected in late stages of the disease [18]. Even a massive infiltration of
both kidneys can remain totally asymptomatic [5]. Urine sediment is usually normal, and
proteinuria< 1 g/d. On the other hand, kidney infiltration can present as acute kidney failure
or moderate chronic kidney disease [6,7,19,20]. In our study, although 10 patients presented a
CLL/SLL-related infiltrate on kidney biopsy, only one patient had a typical enlargement of kid-
neys. The intensity of interstitial infiltration is usually correlated with the severity of kidney
Fig 2. Representative cases of interstitial granulomas. (a) Case 4. Masson trichrome. Interstitial epithelioid and gigantocellular non-necrotizing
granuloma, surrounded by lymphocytes. Original magnification, X 20. (b) Case 6. Hematoxylin and eosin staining. Granuloma associated with severe diffuse
CLL/SLL monomorphic infiltrate. Original magnification, X 40.
doi:10.1371/journal.pone.0119156.g002
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failure, as suggested by the cases of several patients in our study (cases 2, 3, 5, 6) [16,21]. The
mechanisms whereby the infiltrate may contribute to decrease GFR are not univocal, and in
particular not limited to a mechanical compression [22]. Proinflammatory and profibrotic cy-
tokines released by the infiltrating and/or resident cells could play an important role in tubulo-
interstitial injury [23,24]. Accordingly, observational studies have shown that interstitial fibro-
sis was more frequent in areas of interstitial infiltration [16,21]. We found no clear association
between the stage of CLL/SLL and the severity of renal failure, similar to a previous study [25].
The presence of extrarenal tumoral syndrome was generally associated with interstitial infiltra-
tion on the kidney biopsy. An important differential diagnosis for CLL/SLL-related interstitial
infiltration is acute interstitial nephritis. The predominance of T cells, and/or the mixed lym-
phocyte population within interstitial aggregates which respect the normal parenchymal archi-
tecture are strong arguments against the diagnosis of CLL/SLL-related infiltration [21].
Fig 3. Representative cases of MPGN. (a) Case 10. Light microscopy, Masson trichrome staining. Cryoglobulin-related MPGN. Endocapillary proliferation,
fibrinoid necrosis and pseudo-thrombi. Original magnification, X 20. (b) Case 11. Light microscopy, Masson trichrome. Endo- and extracapillary proliferation.
Note the severe CLL/SLL monomorphic infiltrate. Original magnification, X 40. (c) Case 11 (IgG kappa type I cryoglobulin). Immunofluorescence microscopy.
Endomembranous deposits of IgG1, kappa, C3, C1q. Original magnification, X 20. (d) Case 11. Electron microscopy. Subendothelial granular and fibrillar
deposits. Bar = 1200 nm.
doi:10.1371/journal.pone.0119156.g003
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Interstitial granulomatous nephritis is found in less than 1% of native kidney biopsies, and
6–9% of biopsies revealing interstitial nephritis [26,27]. The most frequent causes of granulo-
mas are infections, drug reactions, and inflammatory disorders, which were systematically ex-
cluded in the patients of the present study. In CLL/SLL, the presence of granulomas on kidney
biopsy has been reported twice previously [4,28]. Granulomas are a relatively frequent finding
in patients with Hodgkin’s lymphoma (14%), and non-Hodgkin’s lymphoma (7%), and are
thought to be due to sarcoid reactions against tumor-derived antigens [29]. In this context, the
activation of macrophages is typically mediated by T cells, which may explain the lower preva-
lence in B-cell malignancies. A series of 5 CLL/SLL patients with lymph node and bone marrow
granulomas has been reported, which were related to mycobacteria or sarcoidosis, underlining
the importance of excluding opportunistic infections in this context [30].
The association of glomerular disease in CLL/SLL has been reported in approximately 50
patients, mainly in case reports and in small cases series [31]. The most frequently reported le-
sions are MPGN (36%) and membranous nephropathy (19%), the latter frequently presenting
with atypical characteristics such as proliferative lesions and monotypic deposits [31]. Less
Fig 4. GOMMID (case 15) (a) Light microscopy.Masson trichrome. Mesangial sclerosis with focal mesangial proliferation. Note mild monomorphic focal
CLL/SLL infiltrate. Original magnification, X 10. (b) Light microscopy. Masson trichrome. Mesangial sclerosis and proliferation, capillary deposits. Original
magnification, X 40. (c) Immunofluorescence microscopy. Monotypic Ig lambda deposits. The same fluorescence patern was obtained with an anti-C3
antibody (data not shown). (d) Electron microscopy. Subendothelial organized microtubular deposits, 30-nm external diameter. Bar = 1200 nm.
doi:10.1371/journal.pone.0119156.g004
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frequently, MCD, focal segmental glomerulosclerosis, amyloidosis, and immunotactoid/micro-
tubular glomerulopathies may be found. A difficult issue in this context is to determine wheth-
er or not the glomerular injury is related to the hematologic malignancy. Classical criteria for
paraneoplastic glomerulopathies include a chronological relation (GN often revealing the ma-
lignancy, or simultaneously diagnosed), a suspected pathophysiological link (such as dysprotei-
nemia with or without cryoglobulinemia, cytokine-altered glomerular permeability, or T-cell
dysregulation), and a parallel evolution of the malignancy and the glomerulopathy with specific
cytotoxic treatment [32,33]. In our study, 6/15 patients presented a monoclonal dysproteine-
mia, which is higher than reported in the general population of CLL patients [34,35]. The
monoclonal protein secreted by the B-cell clone can either be directly involved in the pathogen-
esis of the lesions, as is the case in fibrillary glomerulopathy, immunotactoid/microtubular
glomerulonephritis, AL amyloidosis, and type I/II cryoglobulinemia, or indirectly, as in cases
of MPGN not related to cryoglobulinemia.
Fig 5. AHL amyloidosis (case 14) (a) Light microscopy.Masson trichrome staining. Massive amorphous deposits in the mesangium and extending to the
subendothelial space of glomerular capillaries, Bowman’s capsule, the interstitium, the tubular basement membrane and the arterioles. Original
magnification, X 20. (b) Apple green birefringence detected under polarized light. Original magnification, X 20. (c) Immunofluorescence microscopy.
Monotypic Ig lambda deposits. Equally intense staining for heavy and light chains. (d) Electron microscopy. Non oriented, randomly arranged, 10-nm
diameter fibrils. Bar = 1250 nm.
doi:10.1371/journal.pone.0119156.g005
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MPGN is one of the most frequent kidney diseases described in association with CLL/SLL
(Table 8). In our study, 5 patients presented a MPGN, including 2/5 without any detected dys-
proteinemia. Glomerular lesions associated with cryoglobulinemia are either due to immune
complexes or to the direct targeting of native or planted glomerular antigens by the monoclonal
cryoglobulin [8,36]. Irrespective of the mechanism leading to cryoglobulin deposition, glomer-
ular infiltration by macrophages is frequent in this context and is believed to play an important
pathogenic role [37]. Patient 13 presented a monotypic IgGκ fibrillary GN. The presentation of
this patient was unusual since deposits in fibrillary GN are described as polytypic in 90% cases,
and hypocomplementemia is rare [38,39]. In addition, fibrillary GN is exceptionally reported
in CLL/SLL. Interestingly, Schneider et al reported a very similar case, suggesting an important
role for complement activation in the pathogenesis of the glomerular lesions in this context
[40]. As opposed to the glomerular lesions found in cryoglobulin-related MPGN, immunotac-
toid/microtubular glomerulonephritis is usually not associated with macrophage infiltration,
thrombi or vasculitis-like lesions [38]. The microtubular deposits are monotypic, as in patient
Table 6. Post-biopsy follow-up and clinical course.
Case Treatment Pcreat / MDRD
eGFR before/
post treatment
Proteinuria
(g/d)
NS Histology Dialysis CLL/SLL Follow-up Cause of death
before/post
treatment
Alive /
Deceased
Interstitial nephropathy: isolated speciﬁc tumoral interstitial inﬁltrate +/- CLL/SLL-related granulomatosis
1 Cs 185/81 0.3 / < 0.3 / N N Stability 8.3 y
Deceased
Acute alcoholic
hepatitis
Sepsis
2 CHOP Cs 743/173 1 / 0.9 / N N Stability 3 m
Deceased
ND
3 R-FC 178/147 0.9 / 0.7 / N N CR 5 y Alive /
4 Chlorambucil 194/180 0.3 / 0.3 / N N PR 18 m Alive /
5 Chlorambucil 247/609 0.8 / 1.3 / CLL inﬁltrate
Granulomatous
reaction
N Stability 4 y Alive /
5bis N / / / N Y Progression
6 R-Bendamustine Cs 616/296 1.2 / < 0.3 / N Transient
hemodialysis (1
m)
CR 3 m Alive /
Glomerular lesions associated or not to interstitial nephropathy
7 N / / Persistent
NS
N Y Stability 11 y
Deceased
Cardiovascular
disease Sepsis
8 Cs 74/91 6.1 / 0.13 CR and
relapse
MCD N PR 16.5 y
Alive
/
8bis Chlorambucil Cs 71/79 4.6 / <0.3 CR N N CR
9 R-Bendamustine 178/85 6.3 / 1.4 PR N N PR 6 m Alive /
10 N / / / Cryoglobulin-
related MPGN
N Progression 9 y Alive /
10bis Cyclophosphamide
Cs
96/44 13 / <0.3 CR N N CR
Cs: corticosteroids; CHOP: cyclophosphamide+ adriamycin+ vincristine+ prednisone; R-FC: rituximab+ ﬂudarabine+ cyclophosphamide; R-Bendamustine:
rituximab+ bendamustine; Pcreat: Plasma creatinine (micromol/l); NS: nephrotic syndrome; CR: complete remission; PR: partial remission; ESRD: End
Stage Renal Disease; MCD: minimal change disease; Y, yes; N, no; ND, no data available.
doi:10.1371/journal.pone.0119156.t006
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15, their intensity being related to the quantity of the monoclonal component secreted by the
B-cell clone [41]. The microtubular organization present in glomerular deposits can also be
found in the Golgi apparatus of the malignant lymphocytes [41].
The literature describes 12 previous cases of CLL/SLL-related MCD [42–45]. The patho-
physiology of this association is unclear. Both a disturbed pattern of cytokine production by
the B clone and a T-cell dysfunction have been proposed. The parallelism between the evolu-
tion of the hematological disease and the podocytopathy before and after treatment strongly
suggests an immune-mediated link involving the malignant clone.
Immunoglobulin-derived amyloidosis accounts for approximately 85% of amyloidosis diag-
nosed on kidney biopsy [46]. Few cases of CLL/SLL-related amyloidosis have been reported to
date, despite the fact that up to 35% of CLL/SLL patients present abnormal serum free light
chain ratios [47–51]. The reason for this theoretical discrepancy may be that the amount of cir-
culating free light chains is usually moderate in CLL/SLL, and that CLL/SLL clones more fre-
quently produce kappa than lambda light chains, lambda light chains typically being more
amyloidogenic than kappa [50,51]. In our study one patient presented IgG lambda AHL
Table 7. Post-biopsy follow-up and clinical course.
Case Treatment Pcreat /
MDRD eGFR
before/post
treatment
Proteinuria
(g/d)
NS Histology Dialysis CLL/SLL Follow-up Cause of
death
before/post
treatment
Alive /
Deceased
11 Chlorambucil
Chlorambucil;
Rituximab
168/66; 83/
74
14 / 0.19;
5.1/ <0.3
CR and
relapse*; CR
N N Remission and
relapse*; CR
9 y Alive /
12 Chlorambucil 536/180 > 3 / 0.15 CR and
relapse*
Cryoglobulin-
related MPGN
N Remission and
relapse*
8 y
Deceased
Febrile
medullary
aplasia
Acutisation
CLL/ ESRD
CLL inﬁltrate
12bis Chlorambucil Cs 769/790
Dialysis
4.5 / Dialysis Persistent N Y Progression
CHOP
13 Chlorambucil 100/70 > 6 / <0.3 CR N N CR 9 y
Deceased
ND
14 Alkeran Cs 470/700
Dialysis
7 / Dialysis Persistent N Y Stability 9 y
Deceased
ND
15 Chlorambucil;
Chlorambucil;
Fludarabine;
Chlorambucil
79/85 6.1 / < 0.3 CR and
relapse; CR
and relapse*;
CR and
relapse*;
Persistent NS
ITGN CLL
inﬁltrate
N Remission;
Relapse*;
Relapse*;
Progression
16 y Alive /
15bis Rituximab 530/300
Dialysis
> 13 /
Dialysis
PR N Y Stability
Cs: corticosteroids; CHOP: cyclophosphamide+ adriamycin+ vincristine+ prednisone; R-FC: rituximab+ ﬂudarabine+ cyclophosphamide; R-Bendamustine:
rituximab+ bendamustine; Pcreat: Plasma creatinine (micromol/l); NS: nephrotic syndrome; CR: complete remission; PR: partial remission; ESRD: End
Stage Renal Disease; MCD: minimal change disease; ITGN, immunotactoid/microtubular glomerulonephritis; Y; yes; N, no; ND, no data available.
*: Simultaneous relapses in NS and CLL/SLL
doi:10.1371/journal.pone.0119156.t007
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amyloidosis, which is a particularly rare finding, AHL amyloidosis accounting for less than 5%
of Ig-derived renal amyloidosis [46].
This study provides an overview of kidney diseases associated with CLL/SLL requiring biop-
sy due to decreased eGFR and/or NS. Undoubtedly, the clinical context leading to the indica-
tion of histological examination yields a bias in the results of this study. The comparison of our
results with those of autopsy series strongly suggests that the prevalence of isolated CLL/SLL-
related interstitial infiltration is underestimated in the present study. Inversely, the prevalence
of immune-mediated glomerulonephritis is most probably overestimated, compared to the
general population of CLL/SLL patients. Yet, we believe that this study provides a valuable
overview of the renal lesions expected in CLL/SLL patients with a potential indication for kid-
ney biopsy. Due to the broad spectrum of glomerular and interstitial diseases associated with
CLL/SLL, and to the limits of clinicopathological correlations, kidney biopsy remains an essen-
tial tool in selected patients with decreased eGFR and/or NS. An important result of this study
is that the conclusions of the kidney biopsy led to corticosteroid and/or cytotoxic treatment,
and to subsequent favorable renal and hematological responses in a large number of patients.
Table 8. Previously reported series.
Reference Patients Tumoral MPGN MCD Amyloidosis Other
proliferative
GN
Interstitial
granuloma
MN Fibrillary
GN
ITGN MIDD FSGS
n inﬁltrate
Present study 15 10 5 2 1 5 1 1
Moulin et al. 1992
3
13 6 8 1 1 2 1 1
Kowalewska et al.
2011 32
7 7 2 2 1 1 1
Seney et al. 1986 4 2
Dabbs et al. 1986
33
12 1 2 5
Da'as et al. 2001
10
3 1 1
Hill et al. 2002 3 2 1
Barbour et al.
2011
2 1 2
Cameron et al.
1974
2 1 1
Audart et al. 2008 2 1 1
Sethi et al. 2010 2 2
Sanchorawala
et al. 2006 37
2 2
Nasr et al. 2012 3 3
Kourelis et al.
2013 39
4 4
TOTAL 74 25 21 8 8 8 5 4 4 4 3 2
MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; MN, membranous nephropathy; MPGN, membranoproliferative
glomerulonephritis; GN, glomerulonephritis;
MIDD, monoclonal immunoglobulin deposition disease; DN, diabetic nephropathy; ITGN, immunotactoid/microtubular glomerulonephritis.
Single case reports published and not included in these case series are not presented in the Table
doi:10.1371/journal.pone.0119156.t008
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